GLYCART Biotechnology
	Developer of antibody based products for the treatment of unmet clinical needs such as cancer. The company focuses on the development and commercialization of a new generation of antibody products based on its proprietary GlycoMAb technology.
	['antibody ', 'antibody products', '']
Centocor
	Developer of monoclonal antibody technology. The company develops monoclonal antibody-based products for cardiovascular and autoimmune diseases, cancer and inflammation.
	['', 'monoclonal antibody technology', ' ', 'autoimmune disease', ' biopharmaceutical']
SuppreMol
	Developer of therapeutics for the treatment of autoimmune diseases and allergic diseases. The company is focused on development of soluble Fc-gamma receptors (FcyRs), which are recombinant autologous therapeutic proteins with a specific immunoregulatory potential.
	['', 'therapeutic device', ' ', 'autoimmune disease', ' ', 'therapeutic protein', '']
FivePrime Therapeutics
	Developer of protein and antibody therapeutics. The company\'s products include protein based therapeutics for oncology, metabolic disease, type II diabetes, acute myocardial infarction, intestinal bowel disease and infectious diseases and cancer immunotherapy disease areas.
	['', 'antibody therapeutic', ' ', 'cancer immunotherapy', ' ', 'protein therapeutic', '']
Cyrenaic Pharmaceuticals
	Developer of drugs for schizophrenia and bipolar disorder. The company is focused on the development of CYR-101, an innovative antipsychotic for the treatment of schizophrenia.
	['', 'schizophrenia treatment drug', ' ', 'bipolar disorder treatment', ' ', 'drug development', '']
Arbutus Biopharma
	Provider of ribonucleic acid (RNA) interference therapeutics and lipid nanoparticle delivery technology to pharmaceutical partners. The company focuses on the development of internal product candidates that include apolipoprotein B (ApoB) SNALP for the treatment of high cholesterol and polo-like kinase 1 (PLK1) SNALP for the treatment of cancer.
	['', 'RNA interference therapeutics', ' ', 'lipid drug delivery', ' ', 'high cholesterol treatment', ' ', 'therapeutic device', '']
Affomix
	Developer of antibody-based products.
	['', 'antibody screening', ' ', 'antibody product', ' ', 'antibody preparation', '']
Arana Therapeutics
	Provider of biotechnology services. The company is focused on the development of antibody and peptide products for the treatment of inflammatory diseases and cancer.
	['', 'inflammatory diseases', ' ', 'peptide products', ' ', 'research services', '']
BioInvent
	Developer of antibody-based drug therapies for the treatment of cancer. The company has a pipeline of three proprietary antibodies focused on treatment for multiple myeloma, non-Hodgkin lymphoma and medulloblastoma.
	['', 'antibody drugs', ' ', 'drug developer', ' ', 'multiple myeloma', ' ', 'non-Hodgkin lymphoma', '']
NaniRx Therapeutics
	Developer of Precision Immune-Stimulants for the treatment of breast cancer and on Precision Tolerogens for the treatment of autoimmune disorders.
	['', 'drug development', ' ', 'autoimmune disorder', ' ', 'cancer treatment', '']
Automated Cell
	Developer of antibody therapeutic antibodies for the treatment of oncology and immune disease. The company is focused on the development of monoclonal antibody therapeutics for the treatment of cancer.
	['', 'antibody therapeutic', ' ', 'therapeutic treatment', ' ', 'oncology disease', ' ', 'immune disease', ' ', 'monoclonal antibody', '']
Applied Genomics
	Developer of targeted genomics-based diagnostic and therapeutic antibodies for the treatment of human cancer. The company\'s products include Mammostrat which is an immunohistochemistry breast cancer prognostic test, Mammotax which is a single antibody immunohistochemistry test, Pulmotype is a five antibody immunohistochemistry aid for the classification of non-small cell lung cancer and Pulmostrat is a seven antibody prognostic immunohistochemistry test.
	['', 'human cancer', ' ', 'therapeutic antibodies', ' ', 'diagnostic devices', '']
GITR
	Developer of oncological therapies. The company is developing TRX518, a humanized monoclonal antibody that is reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR), for the treatment of cancer.
	['', 'chemotherapeutic treatment', ' ', 'tumor markers', ' ', 'T cell', '']
